Oluyemi Okupe Sells 18,197 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,197 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91. Following the transaction, the chief financial officer owned 284,321 shares of the company’s stock, valued at $9,675,443.63. This trade represents a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.64, for a total transaction of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total transaction of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total value of $79,420.50.

Hims & Hers Health Price Performance

HIMS stock opened at $32.61 on Thursday. The stock’s 50 day moving average price is $27.52 and its 200 day moving average price is $26.46. The firm has a market cap of $7.55 billion, a P/E ratio of -362.37, a PEG ratio of 47.12 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same period in the previous year, the business posted $0.20 EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Capital World Investors boosted its stake in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the last quarter. State Street Corp grew its holdings in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after buying an additional 132,311 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after buying an additional 608,950 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Leerink Partners upped their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Bank of America decreased their price target on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 26th. Truist Financial lifted their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Finally, JPMorgan Chase & Co. cut their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $29.37.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.